AIM: To evaluate the potential of tumor-targeted nanoprobe, N-(2-hydroxypropyl)methacrylamide copolymer-conjugated zinc protoporphyrin (PZP) for photodynamic therapy (PDT) and tumor imaging. MATERIALS & METHODS: Different tumor models including carcinogen-induced cancer were used, PZP was intravenously injected followed by irradiation with xenon or blue fluorescent light on tumor. RESULTS: One PZP 20 mg/kg (ZnPP equivalent) dose with two or three treatments of light at an intensity of ≥20 J/cm2 caused necrosis and disappearance of most tumors (>70%) in different tumor models. We also confirmed PZP-based tumor imaging in carcinogen-induced breast tumor and colon cancer models. CONCLUSION: These findings support the potential application of PZP as a tumor-selective nanoprobe for PDT as well as tumor imaging, by virtue of the enhanced permeability and retention effect.

Institute of Macromolecular Chemistry Academy of Sciences of the Czech Republic Prague Czech Republic; Institute of Macromolecular Chemistry Academy of Sciences of the Czech Republic Prague Czech Republic

Research Institute for Drug Delivery Science Sojo University Ikeda 4 22 1 Kumamoto 860 0082 Japan; Department of General Surgery Sheng Jing Hospital China Medical University Shenyang City Liaoning Province 110004 P R China; Research Institute for Drug Delivery Science Sojo University Ikeda 4 22 1 Kumamoto 860 0082 Japan; Department of General Surgery Sheng Jing Hospital China Medical University Shenyang City Liaoning Province 110004 P R China

Research Institute for Drug Delivery Science Sojo University Ikeda 4 22 1 Kumamoto 860 0082 Japan; Laboratory of Microbiology and Oncology Faculty of Pharmaceutical Science Sojo University Kumamoto Japan; Research Institute for Drug Delivery Science Sojo University Ikeda 4 22 1 Kumamoto 860 0082 Japan; Laboratory of Microbiology and Oncology Faculty of Pharmaceutical Science Sojo University Kumamoto Japan

Research Institute for Drug Delivery Science Sojo University Ikeda 4 22 1 Kumamoto 860 0082 Japan; Research Institute for Drug Delivery Science Sojo University Ikeda 4 22 1 Kumamoto 860 0082 Japan

Zobrazit více v PubMed

McBride G. Studies expand potential uses of photodynamic therapy. J. Natl Cancer Inst. 2002;94(23):1740–1742. PubMed

Wilson BC. Photodynamic therapy for cancer: principles. Can. J. Gastroenterol. 2002;16(6):393–396. PubMed

Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat. Rev. Cancer. 2003;3(5):380–387. PubMed

Nowis D, Legat M, Grzela T, et al. Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene. 2006;25(24):3365–3374. PubMed PMC

Fang J, Seki T, Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv. Drug Deliv. Rev. 2009;61(4):290–302. PubMed

Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011;63(3):136–151. PubMed

Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387–6392. PubMed

Duncan R, Vicent MJ. Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv. Drug Deliv. Rev. 2013;65(1):60–70. PubMed

Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 2011;63(3):131–135. PubMed

Liu J, Ohta S, Sonoda A, et al. Preparation of PEG-conjugated fullerene containing Gd3+ ions for photodynamic therapy. J. Control. Release. 2007;117(1):104–110. PubMed

Sibani SA, McCarron PA, Woolfson AD, Donnelly RF. Photosensitiser delivery for photodynamic therapy. Part 2: systemic carrier platforms. Expert Opin. Drug Deliv. 2008;5(11):1241–1254. PubMed

Oh IH, Min HS, Li L, et al. Cancer cell-specific photoactivity of pheophorbide a-glycol chitosan nanoparticles for photodynamic therapy in tumor-bearing mice. Biomaterials. 2013;34(27):6454–6463. PubMed

Shiah JG, Sun Y, Peterson CM, Straight RC, Kopecek J. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments. Clin. Cancer Res. 2000;6(3):1008–1015. PubMed

Regehly M, Greish K, Rancan F, Maeda H, Böhm F, Röder B. Water-soluble polymer conjugates of ZnPP for photodynamic tumor therapy. Bioconjug. Chem. 2007;18(2):494–499. PubMed

Iyer AK, Greish K, Seki T, et al. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J. Drug Target. 2007;15(7–8):496–506. PubMed

Nakamura H, Liao L, Hitaka Y, et al. Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo . J. Control. Release. 2013;165(3):191–198. PubMed

Jin CS, Cui L, Wang F, Chen J, Zheng G. Targeting-triggered porphysome nanostructure disruption for activatable photodynamic therapy. Adv. Healthc. Mater. 2014;3(8):1240–1249. PubMed

Gabriel D, Zuluaga MF, Lange N. On the cutting edge: protease-sensitive prodrugs for the delivery of photoactive compounds. Photochem. Photobiol. Sci. 2011;10(5):689–703. PubMed

Fang J, Akaike T, Maeda H. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. Apoptosis. 2004;9(1):27–35. PubMed

Sahoo SK, Sawa T, Fang J, et al. Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity. Bioconjug. Chem. 2002;13(5):1031–1038. PubMed

Fang J, Sawa T, Akaike T, et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res. 2003;63(13):3567–3574. PubMed

Iyer AK, Greish K, Fang J, Murakami R, Maeda H. High-loading nanosized micelles of copoly(styrene-maleic acid)-zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor. Biomaterials. 2007;28(10):1871–1881. PubMed

Fang J, Greish K, Qin H, et al. HSP32 (HO-1) inhibitor, copoly(styrene-maleic acid)-zinc protoporphyrin IX, a water-soluble micelle as anticancer agent: in vitro and in vivo anticancer effect. Eur. J. Pharm. Biopharm. 2012;81(3):540–547. PubMed

Editorial. Welcome clinical leadership at NICE. Lancet. 2008;372(9639):601. PubMed

Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 2009;360(6):563–572. PubMed

Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst. 2009;101(15):1044–1048. PubMed PMC

Taieb J, Tabernero J, Mini E, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(8):862–873. PubMed

Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108–1113. PubMed

Sjöblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314(5797):268–274. PubMed

Vicent MJ, Ringsdorf H, Duncan R. Polymer therapeutics: clinical applications and challenges for development. Adv. Drug Deliv. Rev. 2009;61(13):1117–1120. PubMed

Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003;2(5):347–360. PubMed

Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 2009;100(4):572–579. PubMed PMC

Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J. Natl Cancer Inst. 1998;90(12):889–905. PubMed PMC

Moan J, Iani V, Ma LW. Choice of the proper wavelength for photochemotherapy. In: Ehrenberg B, Jori G, Moan J, editors. Photochemotherapy Photodynamic Therapy and Other Modalities. Vol. 2625. Proc SPIE; Bellingham, Washington, DC, USA: 1996. pp. 544–549.

Rigual NR, Shafirstein G, et al. Adjuvant intraoperative photodynamic therapy in head and neck cancer. JAMA Otolaryngol. Head Neck Surg. 2013;139(7):706–711. PubMed PMC

Yano T, Muto M, Minashi K, et al. Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study. Int. J. Cancer. 2012;131(5):1228–1234. PubMed

Kobayashi W, Liu Q, Nakagawa H, et al. Photodynamic therapy with mono-L-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse. Oral Oncol. 2006;42(1):46–50. PubMed

Pech O, Nagy CD, Gossner L, May A, Ell C. Photodynamic therapy of human Barrett's cancer using 5-aminolaevulinic acid-induced protoporphyrin IX: an in-vivo dosimetry study in athymic nude mice. Eur. J. Gastroenterol. Hepatol. 2002;14(6):657–662. PubMed

Seshadri M, Bellnier DA, Vaughan LA, et al. Light delivery over extended time periods enhances the effectiveness of photodynamic therapy. Clin. Cancer Res. 2008;14(9):2796–2805. PubMed PMC

Henderson BW, Busch TM, Vaughan LA, et al. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res. 2000;60(3):525–529. PubMed

Busch TM, Wileyto EP, Emanuele MJ, et al. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen. Cancer Res. 2002;62(24):7273–7279. PubMed

Sitnik TM, Hampton JA, Henderson BW. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br. J. Cancer. 1998;77(9):1386–1394. PubMed PMC

Duncan R, Sat-Klopsch YN, Burger AM, Bibby MC, Fiebig HH, Sausville EA. Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate. Cancer Chemother. Pharmacol. 2013;72(2):417–427. PubMed PMC

Tsukigawa K, Nakamura H, Fang J, et al. Effect of different chemical bonds in pegylation of zinc protoporphyrin that affects drug release, intracellular uptake, and therapeutic effect in the tumor. Eur J Pharm Biopharm. 2015;89:259–270. PubMed

Nakamura H, Etrych T, Chytil P, et al. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. J. Control. Release. 2014;174:81–87. PubMed

Malugin A, Kopecková P, Kopecek J. Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells. J. Control. Release. 2007;124(1–2):6–10. PubMed PMC

Polymer theranostics with multiple stimuli-based activation of photodynamic therapy and tumor imaging

Singlet Oxygen In Vivo: It Is All about Intensity

HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases